TMCnet News
Research and Markets: Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/t528kt/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering. Aripiprazole lauroxil is a novel lipid ester prodrug of aripiprazole that utilizes Alkermes' proprietary LinkeRx technology for once-monthly drug delivery. Once administered IM, aripiprazole lauroxil is converted to aripiprazole, a 5-HT2A antagonist/D2 and 5-HT1A partial agonist that is marketed as Abilify by Otsuka. Alkermes' aripiprazole lauroxil differs from Otsuka/Lundbeck's once-monthly formulation of Abilify, called Abilify Depot, in that it is supplied as a suspension and does not require reconstitution prior to administration. Scope
1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms 4 Disease Management 4.1 Diagnosis 4.1.1 Subjective Assessments 4.1.2 Disease Subtypes 4.2 Treatment Overview 4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 4.2.2 Maintenance Treatment of Schizophrenia 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Opportunity and Unmet Need 6.1 Unmet Needs Overview 6.1.1 Public Awareness 6.1.2 Early Diagnosis and Treatment 6.1.3 Long-Acting and Advanced Drug Delivery Systems 6.1.4 Effective Management of Negative and Cognitive Symptom Domains 6.2 Gap Analysis 6.2.1 Long-Acting Drug Delivery 6.2.2 Treatment of Negative and Cognitive Symptoms 7 Pipeline Assessment 7.1 Overview 7.2 Early-Stage Pipeline Assessment 7.3 Novel Therapeutic Approaches 7.3.1 Negative Symptoms 7.3.2 Cognitive Symptoms 7.4 Long-Acting Drug Delivery 7.5 Technology Trends Analysis 7.6 Key Drugs in Clinical Development 8 Aripiprazole Lauroxil 8.1 Overview 8.2 Efficacy 8.3 Safety 8.3.1 Dosing and Formulation 8.3.2 Potential Clinical Positioning 8.3.3 Potential Commercial Positioning 8.3.4 Pricing and Reimbursement 8.4 SWOT Analysis 8.5 Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/t528kt/aripiprazole
|